Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS

Aberdeen Group plc boosted its position in Oculis Holding AG (NASDAQ:OCS) by 39.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,746,946 shares of the company’s stock after purchasing an additional 493,827 shares during the quarter. Aberdeen Group plc owned about 3.34% of Oculis worth $34,887,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Oculis during the 2nd quarter worth approximately $393,000. Bosun Asset Management LLC acquired a new position in shares of Oculis during the 2nd quarter worth approximately $378,000. Bank of America Corp DE grew its position in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. Finally, Woodline Partners LP grew its position in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on OCS shares. Needham & Company LLC lifted their price objective on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Stifel Nicolaus upped their target price on Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. JPMorgan Chase & Co. began coverage on Oculis in a report on Friday, December 19th. They set an “overweight” rating and a $38.00 price target on the stock. Finally, HC Wainwright boosted their price target on shares of Oculis from $42.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.86.

Oculis Price Performance

Shares of NASDAQ OCS opened at $26.63 on Friday. The company has a market capitalization of $1.54 billion, a P/E ratio of -11.73 and a beta of 0.48. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 5.96. The company has a 50 day simple moving average of $27.44 and a 200-day simple moving average of $22.82. Oculis Holding AG has a 1 year low of $14.00 and a 1 year high of $30.68.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. On average, equities research analysts predict that Oculis Holding AG will post -2.09 earnings per share for the current year.

Oculis Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.